Pneumonias Flashcards
Most common agents typical pneumonia
Strep pneumonia e
H flu
Moraxella
Staph aureus
Most common agents atypical “walking” pneumonia
Mycoplasma. Pneumonia e
Legionella
Chlamydophilia pneumonia e
Chlamydia_psittaci
All hard to culture can’ t be seen on gram
Most live in host cells
Most abundant immune cell pneumonia
Neutrophils
Aspiration pneumonia typical agents
Kleibsella
Anaerobes
Acinetobacter
Alcoholism
Hap most common agents
MR sa
Pseudomonas
Acinetobacter
Enterobacterlacaec
Legionella
Burkholderia
Agents with a higher risk in smoking and copd
Atypical
Pseudomonas
Legionella risks
Travel, hotel, cruises
Staph aureus pneumonia risks
Secondary after flu
Structural lung disease
Bird pneumonia
- Chlamydia-psittaci
Rabbit pneumonia
Francisella-tularensiis
Sheep /goat pneumonia
. Coxiella burnetii
Encapsulated bacteria
S pneumonia
H flu
Protects from phagocytosis
Legionella defenses
Macrophage infector protein
Type 4 secretion system
Grows inside macrophages
Uses iron
S aureus toxin involved in phenomena
Alpha-hemolysi n
- pore forming eytotoxin
Mycoplasma penicillins
No-go, they don’t have a cell wall
Chlamydophiliavirulenufactor
Type 3 secretion system
Lives in macrophages
Enterococci virulence factor
MSR - vanA vancomycin
Outpatient cap Tx
. Macrolide- azithromycin
Or doxy
If recent ab x or high risk:
- azithromycin with ceftriaxone
- respiratory fluroquinolone eg. Levo floxacin
Inpatient cap Tx
- azithromycin with ceftriaxone
- respiratory fluroquinolone eg. Levo floxacin,
In iv form
Pseudomonas empiric coverage
Pip/tazo
MRSA empiric coverage
Vancomycin or linezolid
Antigenic- shift
Major changes due to reassortment
Usually used for flu to mean new subtype
Antigenic drift
Minor changes due to point mutations
Pharyngocongunctival fever
Pharyngitis- conjuncevitis- fever
Adenovirus
Adenovirus genome
Ds DNA
RSV
Paramyxovirus
Ssrna
F protein in envelope Fuses neighboring cells together →multinucleated synciftia
G protein in envelopes → attachment
Palivizumab
Anti-rsv
Prophylaxis for at-risk infants eg. Cyanotic heart failure, bronchopulmonary dysplasia
Not usually needed for tx
Hantavirus
Rural areas, se US
Rodents
Pulmonary edema dt infection ofendothelial cells in lung
Potentially fatal
* thrombocytopenia - prolonged pt and ptt
Measles signs
Fever first
Cough- rinorrhea - conjunctivitis
Kopek spots buccal mucosa
Macalopapular rash
Vzv pneumonia
Ic
Typical vzv signs plus prolonged fever i cough
N odular lung lesions X-ray
CMV pneumonia
Ic
Interstitial pneumonia
Non-productive cough
* Neutropenia (Low)
Elevated lfts
Mucosal ulcers
Flu a/b Tx
Peramivir, zanamimi, oseltamivir
All neuraminidase in hibitors
Indirect flu A Tx
Amantidine
Rimantadine
Both nicotinic (and mixed other) agonists
RSV t x
Ribavirin (also used for hep c)
Palivizumab (mostly prophylactic s
VSV Tx
Acyclovir
CMV Tx
Ganciclovir, valganciclovir
Foscarnet (DNA/RNA polymerase innibitor)
Coronaviruses structure
Enveloped
Linear ss POS sense RNA
COVID entry cell
Type 2 pneumocytes
Lack of surfactant worsens sx
Histoplasmosis risk
Spelunking
Bird/bat droppings
Ohio and Mississippi river
Ic - systemic
Other - mostly asymptomatic, sometimes pneumonia
Histoplasmosis microbe
Yeast-oval, resides in mq
Small
Narrow-based budding
Dimorphic
Histoplasmosis X-ray
Scattered lung nodules with infiltrates
Hilar lymphadenop any
Nonspecific
Blastomycosis risk
Southeast US
Mississippi and Ohio rivers
Southern Canada
Severe blastomycosis presentation
Flu like first
Then:
- severe pneumonia
- possiblerespiratory failin
- warty ulcerated skin granulomas - central scarring,well-defined borders
- bone disease
Ic
Blastomycosis microbe
B dermatitis
Dimorphic
Thick walled yeast-when-warm
Broad based bud
Coccidioses risk
Southwest us
Mexico, South America
San Joaquin valley fever
Cocci sx
60% asymptomatic
Mild pneumonia with fatigue, ha, joint pain
Erythema nodosum or erythema multiforme
Severe in ic → meningitis
Cocci Micro
Highly resistant air borne spores
Spores germinate in thick walled spherules with endospores
Very large
Dimorphic
Aspergillis manifestations
,allergic:
- hay fever type I
- farmer lung type 3
- allergic bronco pulmonaryaspergillosi3 (abpa) combined 1/3
nonin l vasive, or invasive
Aspeogillus risk
Farmers, soil-workers
Farmer lung
Aspirgllosis type 3 Hs ‘”
Dysprea, no wheezing
Fever, chills, cough, sob
Recurring
Exposure-related
ABpA
Aspergillosiscombined 1/3 Hs
Asthma
Lung infiltrates
Eosinophilia
Risk of permanent lung scarring if recurrent
Aspergilloma
Noninvasive fungal ball inside preexisting lung cavities
Cavities created by tb, sarcoidosis, emphysema,
Aspergilloma st
Cough, fatigue
Weight loss
Hemoptysis
Fungal lesions in ear canals, nail beds, and nasal sinuses
Invasive aspergillosis
Necrotic abscesses:
Lung, brain, liver, kidney, gi
Risk:
Neutropenia pts
CD 4 <100
Mucormycosis
Necrotic lesions with black exudate
Upper respiratory/sinus
Fungal ball
Severe: skull invasion
Risk:
Diabetes
Cryptococous risk
Ic ‘
CD 4 <50
Rarely, dt heavy occupational exposure-farmers
Cryptococcus_sx
Pneumonia
Meningitis - new severe ha
Encephalitis ‘
Cryptococcus micro
India ink
Budding yeasts
Capsular halo
Pneumocystis jiroveci risk
Mostly AIDS pts
CD 4 <200
PCP sx
Indolent
Fatigue
Slowly progressive dyspnea
→
High fever
Nonproductive Cough
Hypoxemia <70% Ra
→
Severe ARDS
Pulmonary edema
Elevated LD H
Diffuse bilateral infiltrates with-ground-glass opacities
Methylamine silver stain
PCP microbe
Fungal and protozoan characteristics
Airborne
Opportunistic
CD 4 cutoffs AIDS associated pneumonia’s
PCP <200
Invasive Aspergillus <100
Cryptococcus <50.
Mycobacterium avium <50
Fungistatic drugs
- conazole
Fluconazole
Fungistatic
Narrowspectrum
3 c ‘s:
-Candida
- crypto,occus
-Cocci
Itraconazole
Fungistatic
Broad-spectrum
Voriconazole
Invasive aspergillosis, candidemia
In neutropenia or renal insufficiency
Amphoterrible
Fungitoxic
Severe or disseminated
Broad section
PCP Tx
Tmp-smx
Pentamidine
Prophylaxis in CD 4 <200
Initial Tb response and immune evasion
C3b complement → mq c4 receptor → ingestion
Insufficient destruction b y No
Tb prevents fusion of phagosome with lysosome
-Block sintracellular Ca
- prevent liposome acidification
Growth stage tb
7-21 days post infection
Tb replicates inside mq
Mq rupture → release Tb
Infect more mq → gran. With giant multimucleatd cell, surrounding fibrosis
Il -12 and _ IFN → fever, weight loss
Slow growth phase Tb
21+ days
Continued gran formation
Ghon focus - cavitory necrotic lesion usually in lower lung I peripheral lung fields creactivation later in apex
Hilar lympha.
Thickened pleura
Fever, weight loss, night sweats, hemoptysis
Miliary tb
Systemic,
Ic
Labs Tb
Anemia
High WBC
High esr/crp
Nonspecific
PPD
Quantiferon Gold test- IFN release by T cells in response to mycobacteria
Tb Tx
Rifampin
Isoniazid
Pyrazinamide
Ethambutol
Mycobacterium avium
CD4 < 50
Similar to Tb
Tx macrolide
Pulmonary absuss risk
Aspiration
Most often right lung
Pseudomonas gross sputum characteristics
Blue -green pigment
Fruity odor
Staph aureus gross sputum
Yellow pigment
Compare actinomyas Israelis which has yellow granules
Nocordia Micro
Aerobic
Weaklyacid fast
Branching filaments
Empiric for lung abscess
Meropenem
Nocardia Tx
Sulfonamides eg tmp-smx
Pulmonary abscess X-ray
Air- fluid levels
Sarcoidosis risk fx
Building supply
Construction
Metalwork
Firefighter
Sarcoidosis histology
Non-caseating granul Oma.
Sarcoidosis sx
- Any system
Common:
-Lung-cough, sob, chest pain - eyes
- skin-acne-like lumps
Constitutional
-Malaise
- fever
- weight loss
Young adults >20
Sarcoidosis path
Th 1 CD 4
- ifn-g
→ mq
- ace - diagnostic
- tnf-a
→ maintains gran.
Schaumann bodies
Calcium and protein inside giant cells inside granolas
Sarcoidosis
Sarcoidosis pft
Interstitial
Restrictive
Decreased tl c
Normal to high_fev1/ fvc
Sarcoidosis xray
Hilar adenopathy
Reticular opacities
Sarcoidosis Tx
Oral steroids
Dvt Tx
Heparin
Then warfarin or new gen anticoag if long term indicated
Dvt test
D-dimer
P ocus
Fat emboli risk
Long bone Frx
Pe phys
Low cardi ac output dt low -lv preload
Hypoxem s ia
Tachypnea. -
Dead space
Pe sx
Sob i
Pleuritic cp(inspiration)
Palpitations
Cough
Fever
Dvt sx
Sometimes hemoptysis
End organ hypoperfusion if unstable - impaired rv emptying
Pe EKG
Sinus tach
Rv strain
Right bundle branch block dt dilation
Nonspecific_St and T changes
Pe Tx
Heparin
Xa inhibitors